Low Plasma Membrane Expression of the Miltefosine Transport Complex Renders Leishmania braziliensis Refractory to the Drug
- 1 April 2009
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 53 (4), 1305-1313
- https://doi.org/10.1128/aac.01694-08
Abstract
Miltefosine (hexadecylphosphocholine, MLF) is the first oral drug with recognized efficacy against both visceral and cutaneous leishmaniasis. However, some clinical studies have suggested that MLF shows significantly less efficiency against the cutaneous leishmaniasis caused by Leishmania braziliensis . In this work, we have determined the cellular and molecular basis for the natural MLF resistance observed in L . braziliensis . Four independent L . braziliensis clinical isolates showed a marked decrease in MLF sensitivity that was due to their inability to internalize the drug. MLF internalization in the highly sensitive L . donovani species requires at least two proteins in the plasma membrane, LdMT, a P-type ATPase involved in phospholipid translocation, and its β subunit, LdRos3. Strikingly, L . braziliensis parasites showed highly reduced levels of this MLF translocation machinery at the plasma membrane, mainly because of the low expression levels of the β subunit, LbRos3. Overexpression of LbRos3 induces increased MLF sensitivity not only in L . braziliensis promastigotes but also in intracellular amastigotes. These results further highlight the importance of the MLF translocation machinery in determining MLF potency and point toward the development of protocols to routinely monitor MLF susceptibility in geographic areas where L . braziliensis might be prevalent.Keywords
This publication has 23 references indexed in Scilit:
- Visceral leishmaniasis: what are the needs for diagnosis, treatment and control?Nature Reviews Microbiology, 2007
- Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistance that is conferred to the amastigote stage of Leishmania donovani and persists in vivoInternational Journal of Antimicrobial Agents, 2007
- Phase 4 Trial of Miltefosine for the Treatment of Indian Visceral LeishmaniasisThe Journal of Infectious Diseases, 2007
- Treatment of Bolivian Mucosal Leishmaniasis with MiltefosineClinical Infectious Diseases, 2007
- In vitro activity of perifosine: a novel alkylphospholipid against the promastigote stage of Leishmania speciesZeitschrift für Parasitenkunde, 2007
- Oral miltefosine for the treatment of Indian visceral leishmaniasisTransactions of the Royal Society of Tropical Medicine and Hygiene, 2006
- Miltefosine for New World Cutaneous LeishmaniasisClinical Infectious Diseases, 2004
- Leishmania donovani Resistance to Miltefosine Involves a Defective Inward Translocation of the DrugAntimicrobial Agents and Chemotherapy, 2003
- Short‐Course of Oral Miltefosine for Treatment of Visceral LeishmaniasisClinical Infectious Diseases, 2000
- Use of the green fluorescent protein as a marker in transfected LeishmaniaMolecular and Biochemical Parasitology, 1996